The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Incorporation of molecular characteristics into endometrial cancer management
Open accessAbstract
Histopathological evaluation including subtyping and grading is the current cornerstone for endometrial cancer (EC) classification. This provides clinicians with prognostic information and input for further treatment recommendations. Nonetheless, patients with histologically similar ECs may have very different outcomes, notably in patients with high‐grade endometrial carcinomas. For endometrial cancer, four molecular subgroups have undergone extensive studies in recent years: POLE ultramutated (POLE mut), mismatch repair‐deficient (MMRd), p53 mutant (p53abn) and those EC lacking any of these alterations, referred to as NSMP (non‐specific molecular profile). Several large studies confirm the prognostic relevance of these molecular subgroups. However, this ‘histomolecular’ approach has so far not been implemented in clinical routine. The ongoing PORTEC4a trial is the first clinical setting in which the added value of integrating molecular parameters in adjuvant treatment decisions will be determined. For diagnostics, the incorporation of the molecular parameters in EC classification will add a level of objectivity which will yield biologically more homogeneous subclasses. Here we illustrate how the management of individual EC patients may be impacted when applying the molecular EC classification. We describe our current approach to the integrated diagnoses of EC with a focus on scenarios with conflicting morphological and molecular findings. We also address several pitfalls accompanying the diagnostic implementation of molecular EC classification and give practical suggestions for diagnostic scenarios.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Integrated genomic characterization of endometrial carcinoma
The Cancer Genome Atlas Research Network, & Levine, D. A. (2013) · Nature · doi:10.1038/nature12113 · Cited by 5,784
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810858 · Cited by 2,870
WHO classification of tumours of female reproductive organs
Kurman, R. J., Carcangiu, M. L., Herrington, C. S., & Young, R. H. (2014) · International Agency for Research on Cancer eBooks · Cited by 1,966
Pujade-Lauraine, E., Ledermann, J. A., Selle, F., Gebski, V., Penson, R. T., Oza, A. M., Korach, J., Huzarski, T., Poveda, A., Pignata, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30469-2 · Cited by 1,855
Creutzberg, C. L., van Putten, W. L., Koper, P. C., Lybeert, M. L., Jobsen, J. J., Wárlám-Rodenhuis, C. C., De Winter, K. A., Lutgens, L. C., van den Bergh, A. C., van de Steen-Banasik, E., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02139-5 · Cited by 1,773
Keys, H. M., Roberts, J. A., Brunetto, V. L., Zaino, R. J., Spirtos, N. M., Bloss, J. D., Pearlman, A., Maiman, M. A., & Bell, J. G. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2003.11.048 · Cited by 1,671
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
Colombo, N., Creutzberg, C., Amant, F., Bosse, T., González-Martín, A., Ledermann, J., Marth, C., Nout, R., Querleu, D., Mirza, M. R., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv484 · Cited by 1,386
Self-citationNout, R., Smit, V., Putter, H., Jürgenliemk-Schulz, I., Jobsen, J., Lutgens, L., van der Steen-Banasik, E., Mens, J., Slot, A., Kroese, M. S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)62163-2 · Cited by 1,150
Self-citationConfirmation of ProMisE: A simple, genomics‐based clinical classifier for endometrial cancer
Talhouk, A., McConechy, M. K., Leung, S., Yang, W., Lum, A., Senz, J., Boyd, N., Pike, J., Anglesio, M., Kwon, J. S., et al. (2017) · Cancer · doi:10.1002/cncr.30496 · Cited by 975
A clinically applicable molecular-based classification for endometrial cancers
Talhouk, A., McConechy, M. K., Leung, S., Li-Chang, H. H., Kwon, J. S., Melnyk, N., Yang, W., Senz, J., Boyd, N., Karnezis, A. N., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.190 · Cited by 971
Ott, P. A., Bang, Y.-J., Piha-Paul, S. A., Razak, A. R. A., Bennouna, J., Soria, J.-C., Rugo, H. S., Cohen, R. B., O’Neil, B. H., Mehnert, J. M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.2276 · Cited by 969
Stelloo, E., Nout, R. A., Osse, E. M., Jürgenliemk-Schulz, I. J., Jobsen, J. J., Lutgens, L. C., van der Steen-Banasik, E. M., Nijman, H. W., Putter, H., Bosse, T., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2878 · Cited by 846
Self-citationKommoss, S., McConechy, M. K., Kommoss, F., Leung, S., Bunz, A., Magrill, J., Britton, H., Kommoss, F., Grevenkamp, F., Karnezis, A., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy058 · Cited by 776
Howitt, B. E., Shukla, S. A., Sholl, L. M., Ritterhouse, L. L., Watkins, J. C., Rodig, S., Stover, E., Strickland, K. C., D’Andrea, A. D., Wu, C. J., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2151 · Cited by 684
de Boer, S. M., Powell, M. E., Mileshkin, L., Katsaros, D., Bessette, P., Haie-Meder, C., Ottevanger, P. B., Ledermann, J. A., Khaw, P., Colombo, A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30079-2 · Cited by 641
Self-citationFader, A. N., Roque, D. M., Siegel, E., Buza, N., Hui, P., Abdelghany, O., Chambers, S. K., Secord, A. A., Havrilesky, L., O’Malley, D. M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.5966 · Cited by 516
Stelloo, E., Bosse, T., Nout, R. A., MacKay, H. J., Church, D. N., Nijman, H. W., Leary, A., Edmondson, R. J., Powell, M. E., Crosbie, E. J., et al. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.43 · Cited by 486
Self-citationMakker, V., Rasco, D., Vogelzang, N. J., Brose, M. S., Cohn, A. L., Mier, J., Di Simone, C., Hyman, D. M., Stepan, D. E., Dutcus, C. E., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30020-8 · Cited by 476
Bosse, T., Peters, E. E. M., Creutzberg, C. L., Jurgenliemk-Schulz, I. M., Jobsen, J. J., Mens, J. W., Lutgens, L. C. H. W., van der Steen‐Banasik, E. M., Smit, V. T. H. B. M., & Nout, R. A. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.05.015 · Cited by 451
Self-citationHögberg, T., Signorelli, M., Oliveira, C., Fossati, R., Lissoni, A. A., Sorbe, B., Andersson, H., Grénman, S., Lundgren, C., Rosenberg, P., et al. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.06.002 · Cited by 451
Clinicopathological and molecular characterisation of ‘multiple‐classifier’ endometrial carcinomas
León‐Castillo, A., Gilvazquez, E., Nout, R., Smit, V. T., McAlpine, J. N., McConechy, M., Kommoss, S., Brucker, S. Y., Carlson, J. W., Epstein, E., et al. (2020) · The Journal of Pathology · doi:10.1002/path.5373 · Cited by 415
Self-citationKöbel, M., Ronnett, B. M., Singh, N., Soslow, R. A., Gilks, C. B., & McCluggage, W. G. (2019) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000488 · Cited by 408
Poor Interobserver Reproducibility in the Diagnosis of High-grade Endometrial Carcinoma
Gilks, C. B., Oliva, E., & Soslow, R. A. (2013) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31827f576a · Cited by 401
Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma
Köbel, M., Piskorz, A. M., Lee, S., Lui, S., LePage, C., Marass, F., Rosenfeld, N., Mes Masson, A., & Brenton, J. D. (2016) · The Journal of Pathology: Clinical Research · doi:10.1002/cjp2.53 · Cited by 387
Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer
Mehnert, J. M., Panda, A., Zhong, H., Hirshfield, K., Damare, S., Lane, K., Sokol, L., Stein, M. N., Rodriguez-Rodriquez, L., Kaufman, H. L., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84940 · Cited by 380
Bosse, T., Nout, R. A., McAlpine, J. N., McConechy, M. K., Britton, H., Hussein, Y. R., Gonzalez, C., Ganesan, R., Steele, J. C., Harrison, B. T., et al. (2018) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001020 · Cited by 341
Self-citationPrognostic Significance of POLE Proofreading Mutations in Endometrial Cancer
Church, D. N., Stelloo, E., Nout, R. A., Valtcheva, N., Depreeuw, J., ter Haar, N., Noske, A., Amant, F., Tomlinson, I. P. M., Wild, P. J., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju402 · Cited by 332
Self-citationKurnit, K. C., Kim, G. N., Fellman, B. M., Urbauer, D. L., Mills, G. B., Zhang, W., & Broaddus, R. R. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.15 · Cited by 325
POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
van Gool, I. C., Eggink, F. A., Freeman-Mills, L., Stelloo, E., Marchi, E., de Bruyn, M., Palles, C., Nout, R. A., de Kroon, C. D., Osse, E. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0057 · Cited by 320
Self-citationSimpkins, S. B., Bocker, T., Swisher, E. M., Mutch, D. G., Gersell, D. J., Kovatich, A. J., Palazzo, J. P., Fishel, R., & Goodfellow, P. J. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.4.661 · Cited by 319
Singh, N., Piskorz, A. M., Bosse, T., Jimenez‐Linan, M., Rous, B., Brenton, J. D., Gilks, C. B., & Köbel, M. (2020) · The Journal of Pathology · doi:10.1002/path.5375 · Cited by 316
Self-citationFleming, G. F., Sill, M. W., Darcy, K. M., McMeekin, D. S., Thigpen, J. T., Adler, L. M., Berek, J. S., Chapman, J. A., DiSilvestro, P. A., Horowitz, I. R., et al. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.09.025 · Cited by 300
for the PORTEC Study Group, Wortman, B. G., Creutzberg, C. L., Putter, H., Jürgenliemk-Schulz, I. M., Jobsen, J. J., Lutgens, L. C. H. W., van der Steen-Banasik, E. M., Mens, J. W. M., Slot, A., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0310-8 · Cited by 285
Self-citationMcAlpine, J., Leon‐Castillo, A., & Bosse, T. (2018) · The Journal of Pathology · doi:10.1002/path.5034 · Cited by 254
Self-citationShu, C. A., Pike, M. C., Jotwani, A. R., Friebel, T. M., Soslow, R. A., Levine, D. A., Nathanson, K. L., Konner, J. A., Arnold, A. G., Bogomolniy, F., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1820 · Cited by 232
Liu, Y., Patel, L., Mills, G. B., Lu, K. H., Sood, A. K., Ding, L., Kucherlapati, R., Mardis, E. R., Levine, D. A., Shmulevich, I., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju245 · Cited by 228
Lymphvascular space involvement: an independent prognostic factor in endometrial cancer
Briët, J. M., Hollema, H., Reesink, N., Aalders, J. G., Mourits, M. J. E., ten Hoor, K. A., Pras, E., Boezen, H. M., van der Zee, A. G. J., & Nijman, H. W. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.11.033 · Cited by 221
Guntupalli, S. R., Zighelboim, I., Kizer, N. T., Zhang, Q., Powell, M. A., Thaker, P. H., Goodfellow, P. J., & Mutch, D. G. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.09.017 · Cited by 211
McMeekin, D. S., Tritchler, D. L., Cohn, D. E., Mutch, D. G., Lankes, H. A., Geller, M. A., Powell, M. A., Backes, F. J., Landrum, L. M., Zaino, R., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.8722 · Cited by 210
Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas
de Jonge, M. M., Auguste, A., van Wijk, L. M., Schouten, P. C., Meijers, M., ter Haar, N. T., Smit, V. T. H. B. M., Nout, R. A., Glaire, M. A., Church, D. N., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1443 · Cited by 199
Self-citationHER2-directed therapy: current treatment options for HER2-positive breast cancer
Ahmed, S., Sami, A., & Xiang, J. (2015) · Breast Cancer · doi:10.1007/s12282-015-0587-x · Cited by 185
de Boer, S. M., Powell, M. E., Mileshkin, L., Katsaros, D., Bessette, P., Haie-Meder, C., Ottevanger, P. B., Ledermann, J. A., Khaw, P., Colombo, A., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30120-6 · Cited by 178
Self-citationBosse, T., Nout, R. A., Stelloo, E., Dreef, E., Nijman, H. W., Jürgenliemk-Schulz, I. M., Jobsen, J. J., Creutzberg, C. L., & Smit, V. T. H. B. M. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.07.014 · Cited by 161
Self-citationHER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges
Buza, N., Roque, D. M., & Santin, A. D. (2014) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0416-ra · Cited by 160
Santin, A. D., Bellone, S., Buza, N., Choi, J., Schwartz, P. E., Schlessinger, J., & Lifton, R. P. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1031 · Cited by 160
Sorbe, B., Horvath, G., Andersson, H., Boman, K., Lundgren, C., & Pettersson, B. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2011.04.014 · Cited by 158
Eggink, F. A., van Gool, I. C., Leary, A. F., Pollock, P. M., Crosbie, E. J., Mileshkin, L., Jordanova, E. S., Adam, J., Freeman-Mills, L., Church, D. N., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1264565 · Cited by 148
Self-citationDarvishian, F., Hummer, A., Thaler, H. T., Bhargava, R., Linkov, I., Asher, M., & Soslow, R. A. (2004) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200412000-00004 · Cited by 147
Sloan, E. A., Ring, K. L., Willis, B. C., Modesitt, S. C., & Mills, A. M. (2016) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000783 · Cited by 146
Britton, H. M., Huang, L., Lum, A. M., Leung, S. C. Y., Shum, K., Kale, M., Burleigh, A., Senz, J., Yang, W., McConechy, M. M., et al. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.03.098 · Cited by 118
Bartosch, C., Lopes, J. M., & Oliva, E. (2011) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e318234ab18 · Cited by 101
Costigan, D. C., Dong, F., Nucci, M. R., & Howitt, B. E. (2019) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000583 · Cited by 96
Travaglino, A., Raffone, A., Saccone, G., Luca, C. D., Mollo, A., Mascolo, M., Placido, G. D., Insabato, L., & Zullo, F. (2018) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqy178 · Cited by 96
HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy
Rottmann, D. A., Snir, O. L., Wu, X., Wong, S. T.-L., Hui, P., Santin, A. D., & Buza, N. (2019) · Modern Pathology · doi:10.1038/s41379-019-0358-x · Cited by 88
van Gool, I. C., Rayner, E., Osse, E. M., Nout, R. A., Creutzberg, C. L., Tomlinson, I. P. M., Church, D. N., Smit, V. T. H. B. M., de Wind, N., Bosse, T., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0266 · Cited by 74
Self-citationde Jonge, M. M., Mooyaart, A. L., Vreeswijk, M. P. G., de Kroon, C. D., van Wezel, T., van Asperen, C. J., Smit, V. T. H. B. M., Dekkers, O. M., & Bosse, T. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.11.028 · Cited by 64
Self-citationMolecular insights into the classification of high-grade endometrial carcinoma
Hussein, Y. R., & Soslow, R. A. (2017) · Pathology · doi:10.1016/j.pathol.2017.09.010 · Cited by 62
van Gool, I. C., Ubachs, J. E. H., Stelloo, E., de Kroon, C. D., Goeman, J. J., Smit, V. T. H. B. M., Creutzberg, C. L., & Bosse, T. (2017) · Histopathology · doi:10.1111/his.13338 · Cited by 57
Self-citationYano, M., Ito, K., Yabuno, A., Ogane, N., Katoh, T., Miyazawa, M., Miyazawa, M., Hasegawa, K., Narahara, H., & Yasuda, M. (2019) · Modern Pathology · doi:10.1038/s41379-019-0220-1 · Cited by 56
Germline BRCA -Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity
de Jonge, M. M., Ritterhouse, L. L., de Kroon, C. D., Vreeswijk, M. P. G., Segal, J. P., Puranik, R., Hollema, H., Rookus, M. A., van Asperen, C. J., van Leeuwen, F. E., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0848 · Cited by 54
Self-citationSelecting Adjuvant Treatment for Endometrial Carcinoma Using Molecular Risk Factors
Wortman, B. G., Nout, R. A., Bosse, T., & Creutzberg, C. L. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0825-z · Cited by 32
Self-citationRyan, N. A. J., Wall, J., Crosbie, E. J., et al. (2019) · Histopathology · doi:10.1111/his.13925 · Cited by 24
Cited by
ESGO/ESTRO/ESP Guidelines for the Management of Patients with Endometrial Carcinoma
Concin, N., Matias-Guiu, X., Vergote, I., Cibula, D., Mirza, M. R., Marnitz, S., Ledermann, J., Bosse, T., Chargari, C., Fagotti, A., et al. (2021) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2020-002230 · Cited by 1,989
Self-citationFIGO staging of endometrial cancer: 2023
Berek, J. S., Matias‐Guiu, X., Creutzberg, C., Fotopoulou, C., Gaffney, D., Kehoe, S., Lindemann, K., Mutch, D., Concin, N., & Endometrial Cancer Staging Subcommittee, F. W. C. C. (2023) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.14923 · Cited by 1,000
León-Castillo, A., de Boer, S. M., Powell, M. E., Mileshkin, L. R., Mackay, H. J., Leary, A., Nijman, H. W., Singh, N., Pollock, P. M., Bessette, P., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00549 · Cited by 855
Self-citationMakker, V., MacKay, H., Ray-Coquard, I., Levine, D. A., Westin, S. N., Aoki, D., & Oaknin, A. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00324-8 · Cited by 674
Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Oaknin, A., Bosse, T. J., Creutzberg, C. L., Giornelli, G., Harter, P., Joly, F., Lorusso, D., Marth, C., Makker, V., Mirza, M. R., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.05.009 · Cited by 652
Self-citation
Metadata
- Authors
- Vermij, L., Smit, V., Nout, R., & Bosse, T.
- Venue
- Histopathology
- Publisher
- Wiley
- Published
- 2019-12-17
- Volume
- 76
- Issue
- 1
- Pages
- 52-63
- ISSN
- 0309-0167 (ISSN-L)
- 1365-2559
- OpenAlex
- W2994973919
- Cited by
- 291
- References
- 66
- FWCI
- 27.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.